Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal (Q28372146)

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential i

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Deprenyl in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Hypotension caused by L-dopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

The cardiovascular effects of bromocriptine in Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Bromocriptine in Parkinson's disease: a study of cardiovascular effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Blood pressure and plasma catecholamines in never-treated parkinsonian patients: effect of a selective D1 agonist (CY 208-243).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Chronic L-deprenyl or L-amphetamine: equal cognitive enhancement, unequal MAO inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Deprenyl alters behavior and caudate dopamine through an amphetamine-like action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Monoamine oxidase inhibitors and Sinemet in Shy-Drager syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Clinical pharmacology of monoamine oxidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Effect of amphetamine on the pressor response to tyramine: Formation of p-hydroxynorephedrine from amphetamine in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Deprenyl in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1531-8257%28199903%2914%3A2%3C246%3A%3AAID-MDS1008%3E3.0.CO%3B2-P

10.1002/1531-8257(199903)14:2<246::AID-MDS1008>3.0.CO;2-P

21 January 2018

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

10091617

1 reference

Consolidated OpenCitations Corpus – April 2017